Arista Hemostatic Powder for Total Knee Post Operative Outcomes Study
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests if using Arista MPH® powder during knee replacement surgery can reduce blood loss and improve recovery. It targets patients with osteoarthritis needing knee surgery. The powder helps blood clot faster, reducing bleeding and aiding healing.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
How does this treatment differ from other treatments for breast cancer?
This treatment may involve targeting the ARID1A gene, which is a tumor-suppressor gene that, when re-expressed, can inhibit the growth of breast cancer cells. This approach is unique because it focuses on restoring the function of a gene that is often lost in aggressive breast cancer types, potentially offering a new way to slow down or stop tumor progression.12345
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo total knee arthroplasty with or without Arista hemostatic powder
Post-operative Monitoring
Monitoring of hemoglobin, hematocrit, thigh circumference, and knee range of motion
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Arista
Find a Clinic Near You
Who Is Running the Clinical Trial?
Virtua Health, Inc.
Lead Sponsor
Becton, Dickinson and Company
Industry Sponsor
Tom Polen
Becton, Dickinson and Company
Chief Executive Officer since 2020
Bachelor’s degree from Salisbury University, MBA from Johns Hopkins University
Meera Gopalakrishnan
Becton, Dickinson and Company
Chief Medical Officer
Ph.D. in Biomedical Engineering from the University of Memphis